A clinical randomized trial on dihydroartemisinin piperaquin was conducted with drug resistant malaria patients. The effectiveness to cure the disease through 56 days follow up the recurrent by PCR manifested on 97.4% in DTP group and 100% in A3M group. In second study the rate of recovery was equal in all groups - DTP group 97.4%; DP group 98.7%; A3M group 98.7%. Dihydroartemisenin piperaquin was well tolerated. In less than 3% of patients, there was side effects which can be related to smoking. The preparation is inexpensive, effective, safe with high efficacy to drug resistant malaria parasite.